<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03542227</url>
  </required_header>
  <id_info>
    <org_study_id>B300201734258</org_study_id>
    <nct_id>NCT03542227</nct_id>
  </id_info>
  <brief_title>Standard Operating Procedures for Anti-HPV (Human Papillomavirus) Antibody Detection in First-void Urine</brief_title>
  <acronym>ABSOP-FollowUp</acronym>
  <official_title>Study for the Development of Standard Operating Procedures for Anti-HPV Antibody Detection in First-void Urine: the AB-SOP Follow-up Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universiteit Antwerpen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universiteit Antwerpen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to develop robust analytical protocols for first-void urine sample&#xD;
      preparation and antibody assays to monitor vaccine induced immunity against HPV (Human&#xD;
      Papillomavirus).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants of the HPV V503-004 study (Phase III Clinical trial vaccinating (young) adult&#xD;
      women in Antwerp, EudraCT NUMBER: 2015-005093-38) will be asked if they are willing to&#xD;
      provide two additional urine samples at day 1 and month 7 for biomedical research. The&#xD;
      collected urine will be used for the development and optimisation of robust analytical&#xD;
      protocols for sample preparation and antibody assays.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 11, 2017</start_date>
  <completion_date type="Actual">October 15, 2020</completion_date>
  <primary_completion_date type="Actual">September 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of HPV specific IgG (Immunoglobulin G) in FV urine.</measure>
    <time_frame>Within 6 months after study completion</time_frame>
    <description>To detect HPV specific IgG concentrations (ratio HPV specific IgG/total human IgG), in first-void urine from 63 women to monitor the immune response before and after vaccination with a prophylactic HPV vaccine (Gardasil9).</description>
  </primary_outcome>
  <enrollment type="Actual">63</enrollment>
  <condition>Human Papilloma Virus Infection</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>First-void urine collection</intervention_name>
    <description>Collection of first-void urine (i.e. the initial stream of the urine void) with the Colli-PeeTM device (Novosanis).</description>
    <other_name>FV urine</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      First-void urine samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        In total 63 women are included in this trial. During their study visit at day 0 and 7m&#xD;
        post-vaccination, participants are asked to collect a first-void urine sample with the&#xD;
        Colli-PeeTM device.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant of the HPV V503-004 study at UA/UZA&#xD;
&#xD;
          -  Signing informed consent form (ICF)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>university of Antwerp - centre for the evaluation of vaccination</name>
      <address>
        <city>Wilrijk</city>
        <state>Antwerp</state>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 18, 2018</study_first_submitted>
  <study_first_submitted_qc>May 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2018</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universiteit Antwerpen</investigator_affiliation>
    <investigator_full_name>Pierre Van Damme</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Antibodies</keyword>
  <keyword>Vaccination</keyword>
  <keyword>Self-sampling</keyword>
  <keyword>First-void urine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papillomavirus Infections</mesh_term>
    <mesh_term>Papilloma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

